Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

Pituitary

Volumn 13, Issue 2, 2010, Pages 123-129

  Vilar, Lucio ^a,c   Naves, Luciana A ^b   Azevedo, Monalisa F ^b   Arruda, Maria Juliana ^a   Arahata, Carla M ^a   Moura E Silva, Lidiane ^a   Agra, Rodrigo ^a   Pontes, Lisete ^a   Montenegro, Larissa ^a   Albuquerque, José Luciano ^a   Canadas, Viviane ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^c NONE   (Brazil)

Author keywords

Cabergoline; Cushing's disease; Ketoconazole

Indexed keywords

CABERGOLINE; HYDROCORTISONE; KETOCONAZOLE; ERGOLINE DERIVATIVE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUSHING DISEASE; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEART VALVE REGURGITATION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPOGLYCEMIA; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TRANSSPHENOIDAL SURGERY; DRUG COMBINATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; URINE;

ADULT; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955904726     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0209-8     Document Type: Article

References (37)

1. Pivonello R, De Martino MC, De Leo M et al (2008) Cushing's syndrome. Endocrinol Metab Clin North Am 37:135-149
2. Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526-1540
3. Vilar L, Freitas MC, FariaMet al (2007) Pitfalls in the diagnosis of Cushing's syndrome. Arq Brasil Endocrinol Metab 51:1207-1216
4. Biller BM, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454-2462
5. Newell-Price J, Bertagna X, Grossman AB et al (2006) Cushing's syndrome. Lancet 367:1605-1617
6. Vance ML (2009) Cushing's disease: radiation therapy. Pituitary 12:11-14
7. Smith PW, Turza KC, Carter CO et al (2009) Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 208:1059-1064
8. Dang CN, Trainer P (2007) Pharmacological management of Cushing's syndrome: an update. Arq Bras Endocrinol Metabol 51:1339-1348
9. Moncet D, Morando DJ, Pitoia F et al (2007) Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires) 67:26-31
10. Sonino N, Boscaro M (1999) Medical therapy for Cushing's disease. Endocrinol Metab Clin North Am 28:211-222
11. Lamberts SW, Klijn JG, De Quijada M et al (1980) The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 51:307-311
12. Krieger DT, Amorosa L, Linick F (1975) Cyproheptadine-induced remission of Cushing's disease. N Engl J Med 293:893-896
13. Colao A, Pivonello R, Tripodi FS et al (1997) Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 20:387-392
14. Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94: 223-230
15. Pivonello R, Faggiano A, Di Salle F et al (1999) Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 22:860-886
16. Casulari LA, Naves LA, Mello PA et al (2004) Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 62:300-305
17. Boscaro M, Ludlam WH, Atkinson B et al (2009) Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
18. Vilar L, Freitas MC, Naves LA et al (2008) The role of noninvasive dynamic tests in the diagnosis of Cushing's syndrome. J Endocrinol Invest 31:1008-1013
19. Miller JW, Crapo L (1993) The medical treatment of Cushing's syndrome. Endocr Rev 14:443-458
20. Lamberts SW, Birkenhager JC (1976) Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet 2:811
21. Lamberts SW, Timmermans HA, De Jong FH, Birkenhager JC (1977) The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy. Clin Endocrinol (Oxf) 7:185-193
22. Mercado-Asis LB, Yasuda K, Murayama M et al (1992) Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn 39:385-395
23. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
24. Petrossians P, Ronci N, Valdes-Socin H et al (2001) ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144: 51-57
25. Miyoshi T, Otsuka F, Takeda M et al (2004) Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin- secreting macroadenoma. J Endocrinol Invest 27:1055-1059
26. Tsjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M (2002) Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. J Endocrinol Invest 25: 172-175
27. Pivonello R, Ferone D, de Herder WW et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
28. de Bruin C, Pereira AM, Feelders RA et al (2009) Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 94:1118-1124
29. Godbout A, Manavela M, Danilowicz K et al. (2008) Long-term therapy with cabergoline in Cushing's disease. Program of the 90th annual meeting of the endocrine society, San Francisco, CA, 2008 (p 2-130)
30. Colao A, Lombardi G, Annunziato L (2000) Cabergoline. Expert Opin Pharmacother 1:555-574
31. Lamberts SW, de Lange SA, Stefanko SZ (1982) Adrenocorticotropin- secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab 54: 286-291
32. Croughs RJM, Koppeschaar HPF, Van't Verlaat JW, McNicol AM (1989) Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. J Clin Endocrinol Metab 68:495-498
33. Bricaire L, Brue T (2007) New medical treatments in Cushing's disease. Ann Endocrinol (Paris) 68(Suppl 1):18-20
34. Colao A, Galderisi M, Di Sarno A et al (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocr Metab 93: 3777-3784
35. Czepielewski MA, Rollin GAFS, Bruno OD, Vilar L (2009) Treatment of Cushing's syndrome. In: Vilar L (ed) Clinical Endocrinology, 4th edn. Guanabara Koogan, Rio, pp 459-475
36. Colao A, Di Sarno A, Marzullo P et al (2000) New medical approaches in pituitary adenomas. Horm Res 53(Suppl 3):76-87
37. Pivonello R, De Leo M, De Martino MC et al. (2009) Effeectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing's disease partially responsive to monotherapy with cabergoline. Program of the 11th international pituitary congress, Washington, DC, pp 36-40